Global Accelerator Network On Antibacterial Research Expands

A network of life sciences organisations working together to address antibacterial resistance worldwide has expanded to now include 10 top organisations from six countries, according to CARB-X (Combating Antibiotic Resistant Bacteria), a US-based partnership investing hundreds of millions of dollars in R&D for antibacterial resistance over 5 years.

The short press release is reprinted below, with a link to more information:

CARB-X’s new Global Accelerator Network
brings together knowhow and expertise of 10 leading life sciences organizations from around the world 

CARB-X is expanding its Global Accelerator Network, bringing together 10 world-class organizations from six countries (Denmark, Germany, India, Switzerland, United Kingdom, United States) into a single global network of expertise to provide scientific, technical and business support to the growing numbers of CARB-X-funded antibacterial research projects.

The Network is a one-of-a-kind powerhouse of knowhow in antibacterial drug development, the development of rapid diagnostics, business and regulatory strategy, and other highly specialized areas essential to accelerating CARB-X’s portfolio of funded projects targeting drug-resistant bacteria.

The new accelerators are BaselArea.swiss, BioInnovation Institute (BII), Centre for Cellular and Molecular Platforms (C-CAMP), Foundation for Innovative New Diagnostics (FIND), German Center for Infection Research (DZIF), and the Institute for Life Sciences Entrepreneurship (ILSE). These organizations join existing accelerators: Wellcome Trust, which is also a CARB-X funder, California Life Sciences Institute (CLSI), RTI International and Massachusetts Biotechnology Council (MassBio).

Click here for more information.

———————————-

From the CARB-X website:

“CARB-X currently supports 34 early development antibacterial research projects around the world, and is unique in that it provides both funding and support services for projects. CARB-X aims to increase its portfolio to up to 50 projects this year, including products that would be new classes of antibiotics against Gram-negatives if ultimately approved by the FDA and other regulatory authorities, vaccines and prevention technologies, rapid diagnostics, and other therapeutics.”

“Accelerators provide support tailored to each CARB-X funded project including access to biospecimens and compound libraries, scientific data interpretation, chemistry review, drug and diagnostics development strategy, business and investor relations support, regulatory, intellectual property and partnering support, and any other type of support the company may need. The new Network significantly expands CARB-X’s global reach, expertise and capabilities.”

“CARB-X is a non-profit partnership launched by the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR), the Wellcome Trust, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH).  CARB-X is funded by BARDA, the Wellcome Trust, the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund, and the Bill & Melinda Gates Foundation, with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). CARB-X headquarters are located at Boston University.”

“CARB-X is investing up to $500 million in antibacterial R&D between 2016-2021.”

 

Image Credits: CARB-X.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.